December 2022 Summaries

Detectify has introduced a new feature called Groups, which allows users to organize their assets, such as domains, in a manner that aligns with their team's specific logic and workflow, aiding security teams in managing their expanding attack surfaces more efficiently. With over 3 million domains monitored, the platform aims to simplify navigation by splitting the configuration and insights sections for easier access to relevant information about vulnerabilities and technologies associated with specific domains. Additionally, Detectify has incorporated new crowdsourced vulnerabilities from ethical hackers into its Surface Monitoring and Application Scanning tools, allowing users to stay updated on potential risks. Users can also view technologies hosted on their attack surface and interact with the platform more intuitively through enhanced menu options. The company continues to grow and is actively hiring for various roles, including engineers and product managers.

Recent updates to the Surface Management page have enhanced the visibility and management of technologies across users' attack surfaces, now allowing them to track fingerprinted technologies by domain and providing an overview of all unique technologies. Users can set custom policies to manage these technologies and receive updates on these capabilities. Improvements also include easier API key management, enabling Enterprise customers to name and describe each key for better organization, accessible via the account settings. Attack Surface Custom Policies have been enhanced to help security teams identify risks, with future features planned for more detailed domain and technology-specific policies. Additionally, a new version of the Detectify Recorder Chrome Extension offers a simpler user experience, and customers now receive notifications for failed application scans. The platform has also incorporated new vulnerabilities discovered by ethical hackers, and interested users can explore Detectify further through demos or free trials.